Aktuell
-
Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
Sonntag, 3. September 2017 -
ISHR-ES – Servier Research Fellowship 2017 awarded to Dr Vasco Sequeira Oliveira
Montag, 31. Juli 2017 -
Servier licenses GLPG1972 in osteoarthritis from Galapagos
Freitag, 28. Juli 2017 -
Servier announces an increase in turnover for 2015-2016
Sonntag, 2. Juli 2017 -
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
Donnerstag, 29. Juni 2017 -
Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
Dienstag, 27. Juni 2017 -
Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
Samstag, 3. Juni 2017 -
Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases
Mittwoch, 31. Mai 2017 -
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
Montag, 1. Mai 2017 -
Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
Mittwoch, 26. April 2017 -
Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
Dienstag, 25. April 2017 -
Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
Dienstag, 28. März 2017 -
Dr Claude BERTRAND, General Director of Research and Development at Servier
Montag, 27. März 2017 -
Dr Claude Bertrand, General Director of Research and Development at Servier
Montag, 27. März 2017 -
SERVIER RESEARCH FELLOWSHIP awarded by the INTERNATIONAL UNION OF PHLEBOLOGY UNION INTERNATIONALE DE PHLEBOLOGIE / 2017-2019 submission
Donnerstag, 16. März 2017 -
Servier Research Fellowship awarded by the International Union of Phlebology - Union Internationale de Phlébologie / 2017-2019 submission
Donnerstag, 16. März 2017 -
Servier and Neurochlore join forces to treat autism in children
Dienstag, 14. März 2017 -
Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017
Dienstag, 14. März 2017 -
Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017
Dienstag, 14. März 2017 -
Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
Sonntag, 5. März 2017